Robert L Findling1,2, Lisa Townsend1,3, Nicole V Brown4, L Eugene Arnold5, Kenneth D Gadow6, David J Kolko7, Nora K McNamara8, Devin S Gary2, Dana B Kaplin1, Cristan A Farmer9, Heidi Kipp7, Craig Williams10, Eric M Butter11, Oscar G Bukstein12, Robert Rice10, Kristin Buchan-Page10, Brooke S G Molina7, Michael G Aman10. 1. 1 Division of Child and Adolescent Psychiatry, Johns Hopkins University , Baltimore, Maryland. 2. 2 Department of Psychiatry, Kennedy Krieger Institute , Baltimore, Maryland. 3. 3 Department of Mental Health, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland. 4. 4 Center for Biostatistics, Ohio State University Medical Center , Columbus, Ohio. 5. 5 Department of Psychiatry, Ohio State University , Columbus, Ohio. 6. 6 Department of Psychiatry, Stony Brook University , Stony Brook, New York. 7. 7 Department of Psychiatry and Psychology, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania. 8. 8 Department of Psychiatry, Case Western Reserve University , Cleveland, Ohio. 9. 9 Pediatrics & Developmental Neuroscience Branch, National Institute of Mental Health , Bethesda, Maryland. 10. 10 The Nisonger Center (UCEDD), Ohio State University , Columbus, Ohio. 11. 11 Division of Pediatric Psychology and Neuropsychology, Nationwide Children's Hospital , Columbus, Ohio. 12. 12 Harvard University Children's Hospital , Boston, Massachusetts.
Abstract
OBJECTIVES: Previous "Treatment of Severe Childhood Aggression" (TOSCA) reports demonstrated that many children with severe physical aggression and attention-deficit/hyperactivity disorder (ADHD) responded well to two randomized treatments (parent training [PT]+stimulant+placebo = Basic vs. PT+stimulant+risperidone = Augmented) for 9 weeks. An important clinical question is whether these favorable outcomes are maintained over longer times. METHODS: Clinical responders to the 9-week trial (n = 103/168), defined as Clinical Global Impressions (CGI)-Improvement of much/very much improved plus substantial reduction in parent ratings of disruptiveness, were followed another 12 weeks (21 weeks total) while remaining on blinded treatment. Outcome measures included Clinical Global Impressions scale, Nisonger Child Behavior Rating Form (NCBRF), other parent/teacher-rated scales, laboratory tests, clinician ratings of abnormal movement, and other adverse events (AEs). RESULTS: Parent ratings of problem behavior showed minimal worsening of behavior from end of the 9-week acute trial (expected from regression to the mean after selecting best responders), but outcomes at Extension endpoint were meaningfully improved compared with acute study baseline. As expected, outcomes for Basic and Augmented treatment did not differ among these children selected for good clinical response. During Extension, more Augmented subjects had elevated prolactin; there were no clinically confirmed cases of tardive dyskinesia. Delayed sleep onset was the most frequent Basic AE. We also conducted a last-observation-carried-forward analysis, which included both nonresponders and responders. We found that, at the end of Extension, Augmented subjects had more improvement than Basic subjects on the NCBRF Positive Social subscale (p = 0.005; d = 0.44), the Antisocial Behavior Scale Reactive Aggression subscale (p = 0.03; d = 0.36), and marginally so on the Disruptive Behavior Total subscale (p = 0.058; d = 0.29, the primary outcome). CONCLUSIONS: The medium-term outcomes were good for the participants in both treatment groups, perhaps because they were selected for good response. When nonresponders were included in ITT analyses, there was some indication that Augmented surpassed Basic treatment.
RCT Entities:
OBJECTIVES: Previous "Treatment of Severe Childhood Aggression" (TOSCA) reports demonstrated that many children with severe physical aggression and attention-deficit/hyperactivity disorder (ADHD) responded well to two randomized treatments (parent training [PT]+stimulant+placebo = Basic vs. PT+stimulant+risperidone = Augmented) for 9 weeks. An important clinical question is whether these favorable outcomes are maintained over longer times. METHODS: Clinical responders to the 9-week trial (n = 103/168), defined as Clinical Global Impressions (CGI)-Improvement of much/very much improved plus substantial reduction in parent ratings of disruptiveness, were followed another 12 weeks (21 weeks total) while remaining on blinded treatment. Outcome measures included Clinical Global Impressions scale, Nisonger Child Behavior Rating Form (NCBRF), other parent/teacher-rated scales, laboratory tests, clinician ratings of abnormal movement, and other adverse events (AEs). RESULTS: Parent ratings of problem behavior showed minimal worsening of behavior from end of the 9-week acute trial (expected from regression to the mean after selecting best responders), but outcomes at Extension endpoint were meaningfully improved compared with acute study baseline. As expected, outcomes for Basic and Augmented treatment did not differ among these children selected for good clinical response. During Extension, more Augmented subjects had elevated prolactin; there were no clinically confirmed cases of tardive dyskinesia. Delayed sleep onset was the most frequent Basic AE. We also conducted a last-observation-carried-forward analysis, which included both nonresponders and responders. We found that, at the end of Extension, Augmented subjects had more improvement than Basic subjects on the NCBRF Positive Social subscale (p = 0.005; d = 0.44), the Antisocial Behavior Scale Reactive Aggression subscale (p = 0.03; d = 0.36), and marginally so on the Disruptive Behavior Total subscale (p = 0.058; d = 0.29, the primary outcome). CONCLUSIONS: The medium-term outcomes were good for the participants in both treatment groups, perhaps because they were selected for good response. When nonresponders were included in ITT analyses, there was some indication that Augmented surpassed Basic treatment.
Authors: Lisa M Broidy; Daniel S Nagin; Richard E Tremblay; John E Bates; Bobby Brame; Kenneth A Dodge; David Fergusson; John L Horwood; Rolf Loeber; Robert Laird; Donald R Lynam; Terrie E Moffitt; Gregory S Pettit; Frank Vitaro Journal: Dev Psychol Date: 2003-03
Authors: Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Robert L Findling; Oscar G Bukstein; Nicole V Brown; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi L Kipp; Jayne Schneider; Cristan A Farmer; Jennifer L Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Eric M Butter; Kristin A Buchan-Page; Elizabeth A Hurt; Adrienne B Austin; Sabrina N Grondhuis; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-06-12 Impact factor: 8.829
Authors: Kenneth D Gadow; Nicole V Brown; L Eugene Arnold; Kristin A Buchan-Page; Oscar G Bukstein; Eric Butter; Cristan A Farmer; Robert L Findling; David J Kolko; Brooke S G Molina; Robert R Rice; Jayne Schneider; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-04-13 Impact factor: 8.829
Authors: L Eugene Arnold; Shirley Chuang; Mark Davies; Howard B Abikoff; C Keith Conners; Glen R Elliott; Laurence L Greenhill; Lily Hechtman; Stephen P Hinshaw; Betsy Hoza; Peter S Jensen; Helena C Kraemer; Kristen S Langworthy-Lam; John S March; Jeffrey H Newcorn; William E Pelham; Joanne B Severe; James M Swanson; Benedetto Vitiello; Karen C Wells; Timothy Wigal Journal: J Abnorm Child Psychol Date: 2004-02
Authors: Brooke S G Molina; Stephen P Hinshaw; James M Swanson; L Eugene Arnold; Benedetto Vitiello; Peter S Jensen; Jeffery N Epstein; Betsy Hoza; Lily Hechtman; Howard B Abikoff; Glen R Elliott; Laurence L Greenhill; Jeffrey H Newcorn; Karen C Wells; Timothy Wigal; Robert D Gibbons; Kwan Hur; Patricia R Houck Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-05 Impact factor: 8.829
Authors: Cristan A Farmer; L Eugene Arnold; Oscar G Bukstein; Robert L Findling; Kenneth D Gadow; Xiaobai Li; Eric M Butter; Michael G Aman Journal: Child Adolesc Psychiatry Ment Health Date: 2011-11-10 Impact factor: 3.033
Authors: Justin A Barterian; L Eugene Arnold; Nicole V Brown; Cristan A Farmer; Craig Williams; Robert L Findling; David J Kolko; Oscar G Bukstein; Brooke S G Molina; Lisa Townsend; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2017-10-06 Impact factor: 8.829
Authors: Sabrina N Grondhuis; Cristan A Farmer; L Eugene Arnold; Kenneth D Gadow; Robert L Findling; Brooke S G Molina; David J Kolko; Kristin A Buchan-Page; Robert R Rice; Eric M Butter; Michael G Aman Journal: J Child Adolesc Psychopharmacol Date: 2019-11-15 Impact factor: 2.576